CGEM
NASDAQ
US
Cullinan Therapeutics, Inc. - Common Stock
$14.43
▲ +$0.49
(+3.52%)
Vol 1.1M
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$611.4M
ROE
-41.6%
D/E
0.00
Beta
-0.06
52W
$6–$13
Wall Street Consensus
19 analysts · Apr 20269
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
94.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 80.0%
Next Report
May 06, 2026
EPS Estimate: $-0.84
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.84 | — | — |
| Dec 2025 | $-0.83 | $-0.77 | +$0.06 |
| Sep 2025 | $-0.98 | $-0.77 | +$0.21 |
| Jun 2025 | $-0.85 | $-1.07 | $-0.22 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$47.6M | -$48.5M | -$70.1M | -$50.6M | -$50.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -36.6% | -36.6% | -36.6% | -36.6% | -41.6% | -41.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.83 | 9.83 | 9.83 | 9.83 | 10.45 | 10.45 |
Key Ratios
ROA (TTM)
-39.3%
P/B
1.2
EPS (TTM)
$-3.68
CF/Share
$-3.70
52W High
$13.33
52W Low
$5.68
$5.68
52-Week Range
$13.33
Financial Health
Free Cash Flow
-$38.1M
Net Debt
-$85.6M
Cash
$88.3M
Total Debt
$2.7M
As of Dec 31, 2025
How does CGEM compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CGEM valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.2
▼
51%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CGEM profitability vs Biotechnology peers
ROE
-41.6%
▲
38%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-39.3%
▲
16%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
CGEM financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
10.5
▲
135%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-0.1
▼
106%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CGEM fundamentals radar
CGEM
Peer median
Industry
CGEM profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CGEM vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
MICHAELSON JENNIFER
Officer · Mar 05
8000 shs
MICHAELSON JENNIFER
Officer · Mar 05
4000 shs
MICHAELSON JENNIFER
Officer · Feb 25
1780 shs
AHMED NADIM
Chief Executive Officer · Feb 24
13515 shs
MICHAELSON JENNIFER
Officer · Feb 24
5353 shs
SUMER JACQUELYN L
Officer · Feb 24
3601 shs
JONES JEFFREY ALAN
Officer · Feb 24
4582 shs
FENTON MARY KAY
Chief Financial Officer · Feb 20
4398 shs
AHMED NADIM
Chief Executive Officer · Feb 20
16381 shs
MICHAELSON JENNIFER
Officer · Feb 20
11742 shs
Last 90 days
Top Holders
Top 5: 49.67%Lynx1 Capital Management Lp
14.81%
$115.2M
MPM Bioimpact LLC
12.64%
$98.3M
BVF Inc.
9.50%
$73.9M
Blackrock Inc.
7.27%
$56.5M
Vanguard Group Inc
5.45%
$42.4M
As of Dec 31, 2025